Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Akynzeo versus standard of care for prevention of chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy
2018-002293-44Phase 4Completed
- Sponsor
- CSL Vifor
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in chemotherapy-induced nausea and vomiting (CINV) comparing Akynzeo with Standard of care (2 arms). Primary endpoint: Complete response during overall phase in cycle 1. Started Jun 2018; status: completed.
02
Drugs
palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2018-002293-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002293-44.